Although symptomatic treatment is widely applied in clinical practice， it is often regarded as a relatively low-level therapeutic method. Based on Traditional Chinese Medicine （TCM） state theory， the macroscopic， mesoscopic， and microscopic characterization parameters of TCM symptomatology are horizontally integrated， the full life cycle of states （pre-disease， incipient disease， manifest disease， post-disease） is vertically covered， and the cognitive system of "symptoms" is reconstructed from multiple dimensions. Accordingly， the application approach of symptomatic treatment at different state stages is proposed： implementing preventive intervention in the pre-disease state， strengthening the interception of disease progression in the incipient disease state， regulating dynamic development and treatment in the manifest disease state， and formulating a staged diagnosis and treatment strategy which focuses on functional rehabilitation in the post-disease state.

In the context of the complex and ever-changing spectrum of diseases, the traditional Chinese medicine compatibility of prescription and drugs is no longer able to fully meet the needs of clinical diagnosis and treatment. Therefore, this article is based on the diagnosis and treatment model of the combination of disease, syndrome, and symptom, combined with the development achievements of Western medicine, and explores the principles of formulating traditional prescriptions based on the combination of chief, deputy, assistant, and envoy. This article proposes a formulation principle of composing prescriptions with the diagnosis of syndrome as the chief, the diagnosis of disease as the deputy, the treatment of symptoms as the assistant, and the harmonization of medicine as the envoy. This forms a treatment plan with the core link of syndrome differentiation and treatment, disease differentiation and treatment, symptomatic treatment, detoxification, and efficacy enhancement. The purpose of this article is to address the current clinical challenges such as an increasing disease spectrum and the complexity of syndrome patterns and symptom clusters. It aims to provide new insights into traditional Chinese medicine clinical treatment plans and herbal formulation strategies, with the ultimate goal of improving the clinical effectiveness of traditional Chinese medicine.

Objective:To compare the clinical outcome of whole frozen-thawed embryo transfer in patients with high ovarian response using gonadotropin-releasing hormone agonist (GnRH-a) single trigger or combined with low-dose human chorionic gonadotropin (hCG) dual trigger in the gonadotropin-releasing hormone antagonist (GnRH-A) protocol.Methods:Retrospective cohort study was conducted in Center for Reproductive Medicine, Department of Obstetrics and Gynecology of Peking University Third Hospital between January 2018 to December 2020, and the patients with high ovarian response undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) were divided into GnRH-a single trigger group (group A, n=251) and GnRH-a combined with low-dose hCG dual trigger group (group B, n=741) according to the trigger protocol. The clinical outcome was compared between the two groups. Results:There were no significant differences in clinical characteristics between group A and group B. Estrogen level on the day of trigger, number of embryos formed, number of two pronuclei (2PN) embryos formed, number of high-quality embryos formed and rate of embryo formation in group A were significantly higher than those in group B [(22 905.84±9 513.28) pmol/L vs. (17 200.82±6 811.64) pmol/L, P<0.001; 18.84±9.50 vs. 17.34±8.04, P=0.025; 16.06±8.24 vs. 14.87±7.07, P=0.042; 11.25±6.92 vs. 10.25±5.97, P=0.027; 68.6% (4 730/6 899) vs. 66.5% (12 852/19 326), P=0.002]. However, there were no significant differences in number of oocytes retrieved, mature oocyte rate and high-quality embryo rate between group A and group B (all P>0.05). There were also no significant differences in hCG positive rate, clinical pregnancy rate, abortion rate, ectopic pregnancy rate, persistent pregnancy rate and live birth rate per frozen-thawed embryo transfer between the two groups (all P>0.05). There were no significant differences in cumulative persistent pregnancy rate, cumulative live birth rate, proportion of low birth weight infants and birth defects per ovarian stimulation cycle between the two groups (all P>0.05). The incidence of early-onset severe ovarian hyperstimulation syndrome (OHSS) in group A was lower than that in group B, but there was no significant difference [0% vs. 1.5% (11/741), P=0.075]. Conclusion:The pregnancy outcome of whole frozen-thawed embryo transfer in patients with high ovarian response using GnRH-a single trigger was comparable to dual trigger combined with low-dose hCG in the GnRH-A protocol, and the risk of early onset severe OHSS was low. Therefore, in patients with high ovarian response in IVF/ICSI cycle using GnRH-A protocol, the use of GnRH-a single trigger followed by whole frozen-thawed embryo transfer could be considered as an optimal choice to minimize the risk of early onset OHSS without loss of pregnancy outcome.

Objective:To compare the clinical outcome of whole frozen-thawed embryo transfer in patients with high ovarian response using gonadotropin-releasing hormone agonist (GnRH-a) single trigger or combined with low-dose human chorionic gonadotropin (hCG) dual trigger in the gonadotropin-releasing hormone antagonist (GnRH-A) protocol.Methods:Retrospective cohort study was conducted in Center for Reproductive Medicine, Department of Obstetrics and Gynecology of Peking University Third Hospital between January 2018 to December 2020, and the patients with high ovarian response undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) were divided into GnRH-a single trigger group (group A, n=251) and GnRH-a combined with low-dose hCG dual trigger group (group B, n=741) according to the trigger protocol. The clinical outcome was compared between the two groups. Results:There were no significant differences in clinical characteristics between group A and group B. Estrogen level on the day of trigger, number of embryos formed, number of two pronuclei (2PN) embryos formed, number of high-quality embryos formed and rate of embryo formation in group A were significantly higher than those in group B [(22 905.84±9 513.28) pmol/L vs. (17 200.82±6 811.64) pmol/L, P<0.001; 18.84±9.50 vs. 17.34±8.04, P=0.025; 16.06±8.24 vs. 14.87±7.07, P=0.042; 11.25±6.92 vs. 10.25±5.97, P=0.027; 68.6% (4 730/6 899) vs. 66.5% (12 852/19 326), P=0.002]. However, there were no significant differences in number of oocytes retrieved, mature oocyte rate and high-quality embryo rate between group A and group B (all P>0.05). There were also no significant differences in hCG positive rate, clinical pregnancy rate, abortion rate, ectopic pregnancy rate, persistent pregnancy rate and live birth rate per frozen-thawed embryo transfer between the two groups (all P>0.05). There were no significant differences in cumulative persistent pregnancy rate, cumulative live birth rate, proportion of low birth weight infants and birth defects per ovarian stimulation cycle between the two groups (all P>0.05). The incidence of early-onset severe ovarian hyperstimulation syndrome (OHSS) in group A was lower than that in group B, but there was no significant difference [0% vs. 1.5% (11/741), P=0.075]. Conclusion:The pregnancy outcome of whole frozen-thawed embryo transfer in patients with high ovarian response using GnRH-a single trigger was comparable to dual trigger combined with low-dose hCG in the GnRH-A protocol, and the risk of early onset severe OHSS was low. Therefore, in patients with high ovarian response in IVF/ICSI cycle using GnRH-A protocol, the use of GnRH-a single trigger followed by whole frozen-thawed embryo transfer could be considered as an optimal choice to minimize the risk of early onset OHSS without loss of pregnancy outcome.

Objective:To evaluate the efficacy and safety of programmed death 1 (PD-1), programmed death ligand 1 (PD-L1) immune checkpoint inhibitor (ICI) monotherapy for brain metastasis in advanced non-small cell lung cancer (NSCLC), and to explore the timing of immunomonotherapy and the application of hormone on the efficacy of ICI.Methods:By searching literature in CNKI, Wanfang, VIP, PubMed, CBM, Embase, Cochrane Library and Web of Science databases, the advanced NSCLC patients with brain metastasis who received ICI treatment were identified, including patients with symptomatic brain metastasis who had received hormone therapy or brain surgery or radiotherapy. Meta-analysis was performed on the collected data to evaluate the systemic objective response rate (sORR) and intracerebral tumor objective response rate (iORR), the iORR of whether ICI monotherapy was first-line therapy, and the iORR of whether hormone was used were evaluated, and the incidence of adverse reactions was evaluated.Results:Fifteen studies were finally included, with a total of 4 033 patients, including 917 patients with brain metastasis. The iORR of immunomonotherapy was 26% (95% CI 19%-34%) and the sORR was 28% (95% CI 18%-40%). The iORR of first-line immunomonotherapy was 49% (95% CI 39%-58%). The iORR of symptomatic patients with hormone therapy and asymptomatic patients without hormone therapy was 26% (95% CI 20%-33%) and 19% (95% CI 16%-22%), respectively. The overall incidence of grade 3-4 adverse reactions was 14% (95% CI 11%-17%). Conclusions:The efficacy of ICI monotherapy in the first-line treatment of PD-L1-positive NSCLC patients with brain metastasis is better than that in the subsequent line therapy, and the application of hormone does not affect the efficacy of ICI. ICI monotherapy in the treatment of advanced NSCLC patients with brain metastasis is safe.

Objective To evaluate the clinical efficacy and safety of transcatheter arterial chemoembolization (TACE) with oxaliplatin (OXA), fluorouracil (5-Fu) and pirarubicin (THP) scheme in treating primary liver cancer. Methods A total of 65 patients with primary liver cancer were treated with TACE using infusion of OXA/5-Fu/THP scheme (TACE group). Other 21 patients with primary liver cancer, who were encountered at the Department of Interventional Radiology of authors’ hospital during the same period as the patients of TACE group, received simple transarterial embolization (TAE group). The therapeutic effect, the occurrence of adverse reactions, the progression-free survival time (PFS) and overall survival time (OS) of the two groups were comprehensively evaluated. The results were compared between the two groups. Results In the TACE group, the objective response rate (ORR) and disease control rate (DCR) were 55.4%and 81.5%respectively, and the median PFS and median OS were 11.5 months and 18.5 months respectively. Single factor analysis indicated that patients, who had liver function of Child-Pugh A and received more times or treatment, and who had small-sized tumor and no portal vein tumor thrombus or metastasis, usually had a better prognosis, and the differences were statistically significant (P<0.05). The prognosis of the patients with Barcelona staging (BCLC) B was better than that of the patients with Barcelona staging C, and the difference was statistically significant (P=0.000). Cox multivariate analysis revealed that the portal vein tumor thrombus and tumor metastasis were independent risk factors for the prognosis of the patients. Compared with the TAE group, TACE with OXA/5-Fu/THP scheme could effectively improve the mean progression-free survival time. Conclusion For the treatment of primary liver cancer, TACE with infusion of OXA/5-Fu/THP is clinically effective with fewer adverse reactions.

Objective To evaluate the mid-term and long-term effects of early endovascular emboli-zation in treating ruptured posterior communicating artery aneurysm. Methods Early endovascular embolization therapy was carried out in 36 patients with ruptured posterior communicating artery aneurysm (36 aneurysms in total), and the effects of embolization therapy were evaluated by using Raymond grading method. The unified imaging review program was formulated, and the mid-term and long-term effects were evaluated at half, 1, 2, 3 and 5 years after the treatment. Results The technical success rate was 100% in 36 patients (36 aneurysms in total). Raymond grading evaluation showed that gradeⅠwas seen in 32 patients, gradeⅡ in 2 patients, and grade Ⅲ in 2 patients. Recurrence of aneurysm was found in 5 patients (13.89%) at half (n=1), 2 (n=1), 3 (n=1) and 5 years (n=2) after the treatment. Re-rupture of the recurrent aneurysm was seen in one patient (2.78%). No death occurred during the following-up period. Conclusion Early endovascular embolization for ruptured posterior communicating artery aneurysm can effectively improve the prognosis of subarachnoid hemorrhage, and regular imaging examination can promptly detect the recurrence of aneurysm. Effective interventions are helpful for preventing deterioration and rupture of aneurysm.

Objective Diabetic infrapopliteal artery occlusive disease Deep balloon angioplasty ( percutaneoustransluminal an-gioplasty, PTA) near the middle of the treatment effect and the Department of internal medicine ,conservative treatment .Methods Sixty patients with type II diabetes mellitus complicated with severe infrapopliteal arterial occlusive patients , divided into treatment group (41 cases) and Department of internal medicine treatment group (19 cases),all patients had CTA or MRA or DSA imaging;in-terventional treatment group using Deep balloonPTA ,3 days before operation and postoperative long-term Plavix and culture as anti platelet , blood glucose controltherapy;Department of internal medicine treatment group with control of blood glucose ,precedent in im-proving microcirculation ,debridement dressing and anti infection;observed in 2 week,1 month,3 months,6 months ,1 year,2 years,3 years, two groups were compared after treatment of clinical symptoms and changes signs ,ankle brachial index (ABI),the dorsal artery of foot diameter and blood flow velocity ,evaluation and the total efficiency of 6 months,1 year,2 years,3 years and cut rate .Results Interventional arterial blood flow improved significantly after operation in treatment group ,the clinical symptoms,signs were improved obviously, ankle brachial index improved significantly ,compared with the Department of internal medicine treatment group statistical significance ( P <0.05 ) ,and the total efficiency of 3 years the rate of limb salvage and Department of internal medicine therapy group with significant difference ( P <0.05).Conclusions Deep balloon PTA treating diabetic infrapopliteal artery occlusive disease cura-tive effect,can significantly improve the rate of limb salvage;Department of internal medicine treatment forelderly ,important organ dys-function patients .

To investigate the assessed value of serum lactate dehydrogenase (LDH) and vascular endothelial growth factor (VEGF) for short-term efficacy of transcatheter arterial chemoembolization (TACE). Methods: Serum concentrations of LDH and VEGF from 70 patients with primary liver cancer on the 1st day before therapy and the 3rd, 7th, 14th, and 21st day after TACE ther-apy was determined. The benefit group includes complete remission, partial remission, and stable disease, while the invalid group in-cludes only disease progression. Results:The serum levels of LDH and VEGF in the invalid group were significantly higher than those in the benefit group on the 14th and 21st days after TACE (P<0.05). The percentage changes of the serum concentrations of LDH and VEGF in the invalid group were higher than those in the benefit group on the 21st day after TACE. Percentage changes on the 21st day after TACE were drawn into the ROC curve;the areas under the curve were 65.9%and 85.5%. The optimal cutoff points of LDH and VEGF, which correspond to the Youden index, were 0.272 and 0.745, respectively. Conclusion:The expression levels of VEGF and LDH can be used to assess the short-term efficacy of TACE. A lower expression level corresponds to short-term efficacy.

Objective To investigate the distribution and susceptibility patterns of common uropathogens causing community-acquired urinary tract infection (UTI) in Beijing.MethodsA total of 300non-duplicate isolates were randomly collected from 3 hospitals in Beijing between Jan,1 2010 and Mar,312011.Minimal inhibitory concentrations (MICs) were determined by the broth microdilution methods,which were performed and interpreted according to the guidelines established by the Clinical and Laboratory Standards Institute (CLSI).A panel of 8 antimicrobial agents were tested:amikacin,cefaclor,cefepime,cefoperazone/sulbactam,ciprofloxacin,levofloxacin,gentamicin and nitrofurantoin. Fosfomycin trometamol MICs were determined by the agar-dilution method in cation-adjusted MH agar supplemented with glucose 6-phosphate at a concentration of 25 mg/L as detailed in the guidelines issued by 2010 CLSI. All the Escherichia coli,Klebsiella pneumoniae and Proteus mirabilis strains were screened and confirmed by double-disk synergy test for extended-spectrum β-lactamase (ESBLs).Results Among the organisms cultured,E.coli wasthepredominantpathogen(65.0％ ), followedby Enterococcus(11.7％ ),Staphylococcus( 6.3％ ), Klebsiella pneumoniae( 5. 3％ ), Proteus mirabilis( 4. 7％ ), and Pseudomonas aeruginosa (3.0％).Lower susceptibility rates to ciprofloxacin and levofloxacin (31.4％ -47.4％ ) were observed among all the stains.Amikacin,cefoperazone/sulbactam,nitrofurantoin and fosfomycin trometamol were the most active drugs (92.1％,92.1％,88.4％ and 87.9％ susceptible strains,respectively) among the Gram-negative strains.Isolates of Staphylococcus were highly sensitive to amikacin ( 100.0％ ),cefoperazone/sulbactam (94.7％),nitrofurantoin ( 100.0％ ).Higher susceptibility rates to nitrofurantoin (91.4％) and fosfomycin trometamol (90.0％) were observed in Enterococcus.ESBLs-producing strains accounted for 52.3％ (102/195) in E.coli,43.8％ (7/16) in K.pneumoniae and 14.3％(2/14) in P.mirabilis,respectively.ConclusionsResistance is most common to ciprofloxacin and levofloxacin of all the stains.Currently,the most appropriate agents for the empirical management of uncomplicated UTI seems to be amikacin,cefoperazone/sulbactam,nitrofurantoin and fosfomycin trometamol.